← Back to Screener
Sunshine Biopharma Inc. (SBFM)
Price$1.02
Favorite Metrics
Price vs S&P 500 (26W)-42.30%
Price vs S&P 500 (4W)-10.45%
Market Capitalization$5.05M
All Metrics
Book Value / Share (Quarterly)$4.70
P/TBV (Annual)0.29x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)102.91%
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)-20.40%
Gross Margin (TTM)33.76%
Net Profit Margin (TTM)-16.46%
EPS (TTM)$-1.47
10-Day Avg Trading Volume0.04M
EPS Excl Extra (TTM)$-1.47
Revenue Growth (5Y)248.13%
EPS (Annual)$-1.44
ROI (Annual)-25.94%
Gross Margin (Annual)33.76%
Net Profit Margin (5Y Avg)-1223.93%
Cash / Share (Quarterly)$1.86
Revenue Growth QoQ (YoY)-10.61%
ROA (Last FY)-19.87%
Revenue Growth TTM (YoY)4.10%
EBITD / Share (TTM)$-1.42
ROE (5Y Avg)-1211.75%
Operating Margin (TTM)-17.15%
Cash Flow / Share (Annual)$-1.26
P/B Ratio0.22x
P/B Ratio (Quarterly)0.26x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)-0.11x
Net Interest Coverage (TTM)-37.74x
ROA (TTM)-19.48%
EPS Incl Extra (Annual)$-1.44
Current Ratio (Annual)4.17x
Quick Ratio (Quarterly)1.95x
3-Month Avg Trading Volume0.04M
52-Week Price Return-15.57%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$4.31
P/S Ratio (Annual)0.14x
Asset Turnover (Annual)1.21x
52-Week High$2.43
Operating Margin (5Y Avg)-1197.75%
EPS Excl Extra (Annual)$-1.44
CapEx CAGR (5Y)270.37%
26-Week Price Return-33.55%
Quick Ratio (Annual)1.95x
13-Week Price Return-16.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.17x
Enterprise Value$-4.07
Revenue / Share Growth (5Y)4.23%
Asset Turnover (TTM)1.18x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.94x
Pretax Margin (Annual)-16.40%
Cash / Share (Annual)$1.86
3-Month Return Std Dev49.83%
Gross Margin (5Y Avg)37.34%
Net Income / Employee (TTM)$-0
ROE (Last FY)-25.94%
Net Interest Coverage (Annual)-8.18x
EPS Basic Excl Extra (Annual)$-1.44
Receivables Turnover (TTM)9.91x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.47
Receivables Turnover (Annual)9.91x
ROI (TTM)-24.99%
P/S Ratio (TTM)0.14x
Pretax Margin (5Y Avg)-1222.65%
Revenue / Share (Annual)$8.73
Tangible BV / Share (Annual)$4.31
Price vs S&P 500 (52W)-50.67%
Year-to-Date Return-16.26%
5-Day Price Return4.01%
EPS Normalized (Annual)$-1.44
ROA (5Y Avg)-141.82%
Net Profit Margin (Annual)-16.46%
Month-to-Date Return-0.96%
Cash Flow / Share (TTM)$-1.09
EBITD / Share (Annual)$-1.42
Operating Margin (Annual)-17.15%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-156.30%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.47
P/TBV (Quarterly)0.29x
P/B Ratio (Annual)0.26x
Inventory Turnover (TTM)1.94x
Pretax Margin (TTM)-16.40%
Book Value / Share (Annual)$4.70
Price vs S&P 500 (13W)-19.13%
Beta-8.49x
Revenue / Share (TTM)$7.48
ROE (TTM)-24.99%
52-Week Low$0.95
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SBFMSunshine Biopharma Inc. | 0.14x | 4.10% | 33.76% | — | $1.02 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Sunshine Biopharma Inc is a pharmaceutical company operating across oncology and antiviral therapeutics, with a commercial portfolio of generic prescription drugs in Canada and over-the-counter supplements. The company is developing a proprietary pipeline including K1.1, an mRNA therapeutic targeting liver cancer, and SBFM-PL4, a protease inhibitor candidate for SARS coronavirus infections.